Market Highlights:

The global carcinoembryonic antigen market Share is expected to grow 6.7% during the forecast period.

Carcinoembryonic Antigen or CEA is a kind of glycoprotein produced by cells of the gastrointestinal tract during foetal development which is involved in cell adhesion. Its level is low in healthy adults. However, high levels of CEA are marked in cancerous conditions. The normal range for CEA in an adult who is non-smoker is estimated to be about <2.5 ng/ml. Similarly, for smokers the level of CEA ranges about <5.0 ng/ml. Therefore, on the basis of CEA profiling a number of cancers including colorectal, pancreatic, breast, lung, and others can be easily diagnosed. It is reported that the CEA based diagnostic assays are mostly used for the detection of colorectal cancer.

Factors such as increasing awareness, technological advancements in the medical sector and proteomics, increasing prevalence of colorectal cancer, and lifestyle changes involving the consumption of junk foods, alcohol, and others provides favourable backgrounds for the market growth.

However, side effects related to the CEA test including unreasonable bleeding followed by blacking out, hematoma, risk of infection, erroneous readings and low healthcare expenditures in middle- and low-income countries is estimated to restrain the market growth during the forecast period.

Market Players:

Some of key players profiled in the report are Lee BioSolutions, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated., Correlogic Systems, Inc, Genway Biotech, Inc., Abbott., RayBiotech, Inc., Abcam plc., Biocare Medical, LLC, and Biocare Medical, LLC.

Regional Analysis:

North America leads the global carcinoembryonic antigen market owing to high prevalence of colorectal cancer, increasing obese population, lifestyle changes, and increasing acceptance of new technologies. Moreover, increasing government support for research and development propels the market growth. For instance, in 2015, NIH received USD 1 billion for life science and health-related research and development programs.

Europe stands second in the global antigen typing procedure.  Factors such as advanced treatment facilities, rising skilled medical professionals and increasing prevalence of cancer drives the market within the region. In the year 2012, WHO suggested that cancer is the main cause of premature death in 28 of 53 countries in Europe.

Asia Pacific is expected to be the fastest region in the global carcinoembryonic antigen market. This can be attributed due to the increasing prevalence of gastro-intestinal cancer, rising health awareness, availability of new treatment methods, rising government support. Moreover, growing healthcare expenditure boosts the market.

The Middle East & Africa holds the least share in the market owing to the presence of low income countries and low healthcare expenditure, especially within the African region. Within this region, the Middle East leads the market due to the presence of developed economies like United Arab Emirates, Saudi Arabia, and others. Moreover, developed healthcare infrastructure and rising number of skilled medical professionals fuels the regional market.

Market Segmentation:

The global carcinoembryonic antigen market has been segmented on the basis of application, sampling, and end user.

Based on application, the market has been segmented into colorectal, pancreatic, breast, lung cancer, and others.  

Based on sampling, the market has been segmented into antecubital, peritoneal, pleural, serebrospinal, and others.

Based on the end users, the market has been segmented into hospitals, diagnostic centers, research centers, and others.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com